Services

The Human Pluripotent Stem Cell Core offers the following services:


Reprogramming human somatic cells to induced pluripotent stem cells

Expanding human embryonic stem cell lines

Differentiation studies using both human embryonic as well as human iPS cells

1. In the Core Facility, we are using the latest protocols to generate, clonally expand and characterize human induced pluripotent stem (hiPS) cells from a variety of tissue-type fibroblasts. We generate iPS cells using lentiviral transduction and feeder-free conditions. However, in the upcoming 2-3 months we will be able to generate integration-free iPS cells. Prior to handing these cell lines to investigators, we perform quality control experiments to verify the pluripotency of the iPS cells. We are also working on reprogramming peripheral blood cells as well as keratinocytes.

2. We are using the most current protocols to maintain and expand hES cell lines under feeder-free conditions on substrates such as matrigel or fibronectin.  For researchers that have purchased human embryonic stem cell lines but do not have the expertise in manipulating these cells, we can thaw, validate, expand and cryopreserve them.

3. We are using current protocols as well as generating new ones to differentiate hES and hiPS cells into a variety of cell types (neuronal progenitor cells, endothelial cells, retinal progenitor cells as well as cardiomyocytes). We are optimizing protocols for hES/hiPS differentiation into mesenchymal, hepatocyte as well as other cell types.

4. The Core Facility has a bank of antibodies that will be used to fully characterize the cells in both the undifferentiated as well as the differentiated state.

5. We also perform karyotype analysis on every hES and hiPS cell line.

Available hES lines in the Core Facility: the federally approved H1, H7 and H9 hES cell lines.

Other services that we provide:

1. Generation of hES or hiPS cell lines silenced for a variety of genes using siRNA or lentiviruses.

2. Generation of large numbers of hES and hiPS cells for high-throughput screening studies.